Table S1. List of all 64 patients with known germline mutationsâ=âgroup K. With the exception of mutations in MUTYH, all mutations were in a heterozygous state. (XLSX 16 kb)
Objectives: During targeted therapy, tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique resistance mechanisms. Sequential profiling of plasma cell-f
Genomic profiles of tumor DNA obtained from biopsies were systematically compared to corresponding samples of circulating cell free tumor DNA. The aim was to investigate correspondance between numeric
